TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06652893

Intervention type: DRUG
Intervention: Sinovial
Description: A single intra-articular injection of hybrid HA complex, Sinovial® HL (IBSA Pharmaceuticals, Italy, patent number WO/2012/032151 ) in the knee was performed from the lateral approach to the suprapatellar recess using ultrasound. For the ultrasound-guided infiltration method, a sterile linear probe with a 20 G guide was used to visualize the joint suprapatellar recess and avoid intrasynovial infiltration. The patient was positioned supine with the knee in full extension. From the lateral approach to the suprapatellar recess, HA was then injected into the knee joint, verifying intra-articular positioning in real-time via ultrasound imaging (direct visualization of viscous fluid or air bubbles).~Patients did not receive anti-inflammatory or pain-relieving drugs in the week before the first injection . Patients were evaluated at four time points: at baseline and after 28, 42, 84, and 168 days after the intervention. At each evaluation, clinical data relating to the status of the disea
Study: NCT06654167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low temperature (16℃) group
Description: The exposure group will be exposed to low temperature (16℃) in a chamber for about 2 hours, resting during the whole period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate temperature (22℃) group
Description: The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
Study: NCT06654921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham RIC will be performed by the same electric auto-control device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (60 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study: NCT06654817

Intervention type: DRUG
Intervention: Ofatumumab subcutaneous injection
Description: To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.
Study: NCT06654804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid
Description: Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
Study: NCT06654466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.
Description: The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
Study: NCT06592196

Intervention type: OTHER
Intervention: stain
Description: This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
Study: NCT06598904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma diffuser with single-note lavender essential oil
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note lavender essential oil into the aroma diffuser reservoir containing 120 ml of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma diffuser with single-note orange essential oil
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note orange essential oil into the aroma diffuser reservoir containing 120 ml of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aroma diffuser with deionized water
Description: In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of deionized water.
Study: NCT06600919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Music Therapy Session
Description: Upon admission to the operating room:~Patients in the music therapy group will undergo a 20-minute music therapy session while lying on a stretcher in a designated room. This session will be conducted using the Music Care® application (https://www.music.care).~The sessions are standardized and divided into several phases, following a U-shaped sequence. The effect of this U-sequence is first achieved by a phase of reduced tempo, instrumental density, frequency, and sound volume , followed by a phase of reactivation .~Patients will be allowed to choose the musical style based on their preferences (influenced by their musical tastes and ethnicity). Given the ethnically diverse population of Réunion Island, a wide range of musical preferences is expected.
Study: NCT06589141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: Metformin (500 to 2000 mg orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlyBURIDE 2.5 MG Oral Tablet
Description: Glyburide (2.5 mg to 20 mg orally)
Study: NCT06593873

Intervention type: OTHER
Group type: OTHER
Intervention: Use of typodont head model in addition to theoretical periodontal education
Description: Use of typodont phantom head model in addition to theoretical periodontal education

Intervention type: OTHER
Group type: OTHER
Intervention: Theoretical periodontal education
Description: Theoretical periodontal training only
Study: NCT06597227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal radical gastrectomy
Description: Proximal radical gastrectomy : Dissection of lymph nodes No.1,2,3a,4sa,4sb,7,8a, 9, 11p, 11dare recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: double channel anastomosis is recommended, and other anastomosis methods can be carried out according to the surgeon\&#39;s habit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total radical gastrectomy
Description: total radical gastrectomy : Dissection of lymph nodes No.1-7, 8a, 9, 11p, 11d, 12a are recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: Roux⁃en⁃Y anastomosis is recommended
Study: NCT06589206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified design of twin block
Description: Vacuum formed twin block appliance with sagittal blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified design of twin block
Description: Vacuum formed twin block appliance with sagittal blocks
Study: NCT06589349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: Physiological parameters will be measured in the Day (10:00) - Night (22:00) cycle for 3 days, just before being taken into kangaroo care in the experimental group, and when the kangaroo care is terminated, the baby will be measured in the mother's arms. Then, the mother and baby will be placed in kangaroo care for a minimum of 70 minutes
Study: NCT06594198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral monitor
Description: The study procedure consists of monitoring the values of 3 cerebral parameters: SctO2, bcSEF and ANI measured by the ARGOS sensor. These 3 parameters will be recorded and compared after the intervention with 3 parameters considered as standard: SctO2 measured by the INVOS 7100 cerebral oximeter, the bispectral index (BIS) measured by the BIS monitor and the ANI measured by the MDoloris monitor. These 3 reference parameters are once again usually monitored and recommended for all cardiac surgery.
Study: NCT06587984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: One-time text message reminder with information about getting flu vaccine at CHOP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: One-time text message reminder with information about getting flu vaccine at CHOP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: One-time text message reminder with information about getting flu vaccine at CHOP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: One-time text message reminder with information about getting flu vaccine at CHOP
Study: NCT06591910

Intervention type: DRUG
Intervention: Chemoimmunotherapy
Description: Induction Serplulimab combined with chemotherapy

Intervention type: PROCEDURE
Intervention: Surgery
Description: After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.

Intervention type: RADIATION
Intervention: Radiation
Description: After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.
Study: NCT06586840

Intervention type: OTHER
Intervention: rescue analgesia
Description: . If NRS is 4 or higher in the postoperative recovery room, 100 mg of intravenous tramadol will be administered as rescue analgesia

Intervention type: OTHER
Intervention: rescue analgesia
Description: . If NRS is 4 or higher in the postoperative recovery room, 100 mg of intravenous tramadol will be administered as rescue analgesia

Intervention type: PROCEDURE
Intervention: Adductor Canal Block
Description: For Group I, after patients are placed in the supine position, a linear ultrasound probe (13-6 MHz) will be used to identify the superficial femoral artery in the short axis, lateral to the Sartorius muscle, and anterior to the adductor magnus muscle in the adductor canal. A 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially under sterile conditions, and 20 mL of 0.5% bupivacaine will be injected after negative aspiration.

Intervention type: PROCEDURE
Intervention: Adding an IPACK Block to the Adductor Canal Block
Description: For Group II, 20 mL of 0.25% bupivacaine will be injected into the Adductor Canal after spinal anesthesia. With the knee flexed, a convex probe (3.5-6 MHz) will be placed in the popliteal region to identify the popliteal artery in the short axis. The ultrasound probe will be moved distally after the common peroneal and tibial nerves are identified. The probe will be gradually moved towards the popliteal fossa until the popliteal vessels are identified superficially. The ultrasound probe will be moved to the level where the femoral condyles merge with the femoral shaft. The popliteal artery, tibial and peroneal nerves will be visualized to identify the space between the femur and the popliteal artery. In the area known as iPACK, a 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially, and 20 mL of 0.25% bupivacaine will be injected after negative aspiration.
Study: NCT06589427

Intervention type: OTHER
Intervention: Invasive ventilation.
Description: Patients were subjected to invasive ventilation.
Study: NCT06591273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab-dyyb Biosimilar (Remsima)
Description: Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
Study: NCT06595433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: In the PAPE 90% protocol, participants performed a general warm-up (e.g., jogging on a treadmill) for 5 minutes and a weightlifting-specific warm-up for 5 minutes, followed by 2 minutes of rest. After resting, they were asked to perform ten repetitions of dip squats with body weight and rested for 1 minute.Then, unlike the unloaded protocol, they performed three repetitions of dip squats with 90% of their one-repetition maximal dip squats and rested for 4 minutes. After resting, they performed a snatch to exhaustion with 75% of their maximum snatch weight. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions between sets was recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: In the PAPE 50% protocol, 5 minutes of general warm-up (jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up were followed by 2 minutes of rest as in the other protocols. After resting, they were asked to perform ten repetitions of body-weighted dip squats and rested for 1 minute. Then, unlike the unloaded and PAPE 90% protocols, they performed eight repetitions of bottom squats with 50% of their maximal bottom squats for one repetition and rested for 4 minutes. After resting, they performed snatches with 75% of their maximum snatch weight until exhaustion. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions was recorded for statistical analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: unloaded protocol
Description: In the unloaded protocol, subjects performed a 5-minute general warm-up (e.g., jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up followed by 2 minutes of rest. After resting, they performed ten repetitions of bottom squats with their body weight and then rested for 1 minute. After rest, they performed the snatch movement with 75% of their maximum snatch weight until exhaustion. Then, they rested for 2 minutes and again performed the snatch with 75% of their maximum snatch weight until exhaustion. The maximum number of snatch repetitions performed by the weightlifters was recorded for statistical analysis.
Study: NCT06585813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant
Description: we placed our implants and simultaneously grafted either fibroguide or CTG and after 3 months we did the second stage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant
Description: we placed our implants and simultaneously grafted either fibroguide or CTG and after 3 months we did the second stage surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrogide membrane
Description: we were comparing the efficacy of Fibrogide with the Connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft
Description: the control group was the connective tissue graft group and the test group was the Fibrogide group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: second stage
Description: second stage to determine the thickness gained after the graft and to place a healing abutment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: second stage
Description: second stage to determine the thickness gained after the graft and to place a healing abutment
Study: NCT06595511

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Entrainment-Integrated Cognitive Game Kit
Description: Active comparator group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, at least five days a week, for three months.
Study: NCT06588790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rapid testing
Description: Participants will be provided with rapid diagnostic tests for HIV, pregnancy and malaria (in Kenya and Zambia only) for on-demand, at-home self testing if/when indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community health worker rapid testing
Description: Participants will have access to rapid testing through a community health worker who will conduct rapid testing in the home or at a community-based location when indicated.
Study: NCT06593002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic play
Description: The children in the experimental group were given a therapeutic toy designed for them by the student nurse half an hour before the treatment, the toy and game were introduced, and they were allowed to play with this toy for half an hour, accompanied by the student nurse.
Study: NCT06600048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine
Description: Patients will receive 1.5 ml (30 mg) 0.5% hyperbaric prilocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Patients will receive 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine.
Study: NCT06597630

Intervention type: OTHER
Intervention: Tissue specimens were stained by histopathology of hematoxylin-eosin
Description: Whole slide images were created by scanning the complete histologic slide to produce high-resolution digital files of the histopathology of hematoxylin-eosin and CYP11B2 immunostained sections.Tissue sections of all blocks from each resected adrenal were evaluated by hematoxylin and eosin and CYP11B2 immunostaining and adrenal specimens were categorized as classical or nonclassical histopathologic findings of unilateral PA according to the HISTALDO consensus; Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing
Study: NCT06592339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0616
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0616
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0616
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0616
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0616
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0616
Description: oral administration
Study: NCT06588517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Modified-Release Tablets
Description: take the tablet under fed condition, 1 tablet at a time, once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone Tablets
Description: ake the tablet under fed condition, 1 tablet at a time, three times a day.
Study: NCT06601400

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) with xenograft
Description: After atraumatic extraction of the non-restorable tooth, Implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft and erythropoietin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft alone
Description: After atraumatic extraction of the non-restorable tooth, implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft alone.
Study: NCT06591312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study: NCT06655441

Intervention type: DRUG
Group type: OTHER
Intervention: 3% trehalose
Description: ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% trehalose
Description: ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles
Study: NCT06587295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular ACM-CpG Monotherapy (Escalation)
Description: Dose escalation for ACM-CpG monotherapy administered via intramuscular injection will similarly be conducted using traditional 3+3 dose escalation. Three dose levels have been planned. If the patient experiences a DLT or two Grade ≥ 2 drug-related toxicity, the dose level will be expanded according to a 3+3 design. The safety and tolerability of each dose level will be assessed by the study team after all patients enrolled in the dose level have been followed for at least 21 days after the first dose of the ACM-CpG (DLT observation period). Once the MTD is reached, the RP2D will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular ACM-CpG Monotherapy (Expansion)
Description: Patients will be administered ACM-CpG monotherapy at a dose determined in the dose escalation phase.
Study: NCT06600789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7439 Capsules (0.5 mg, 1mg, 3mg)
Description: CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed.
Study: NCT06588920

Intervention type: BEHAVIORAL
Intervention: Cognitive function, gait, and electroencephalogram
Description: Measurement of cognitive function, gait performance, and electroencephalogram

Intervention type: BEHAVIORAL
Intervention: Cognitive function, gait, and electroencephalogram
Description: Measurement of cognitive function, gait performance, and electroencephalogram